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Timur P. Sarac, MD,a and Kenneth Ouriel MD,c Cleveland, Ohio; and New York, NY
Objective: Replacing heparin with bivalirudin has been beneficial in patients undergoing coronary intervention and
coronary artery bypass. The use of this alternative anticoagulant during peripheral bypass operations has not been
studied. Concerns over distal thrombosis using this direct thrombin inhibitor (DTI) prompted a single-arm, open-label,
pilot prospective trial of bivalirudin in patients undergoing lower extremity bypass to assess perioperative safety and
efficacy.
Methods: Between 2006 and 2007, 18 patients met criteria for enrollment and underwent primary lower extremity bypass
using bivalirudin. All patients had severe symptomatic atherosclerotic disease requiring lower extremity bypass.
Bivalirudin at a bolus dose of 0.75 mg/kg and continuous infusion of 1.75mg/kg/hr was used as the sole anticoagulant.
Results:Patients (mean age, 67 years) underwent femoral-popliteal (n 14) or femoral-tibial (n 4) bypass preferentially
using saphenous vein (83%). Mean operative time was 261 minutes, with bivalirudin infusion time of 95  26 minutes
(mean  standard deviation). Reliable anticoagulation was achieved with weight-based dosing with activated clotting
time values at baseline (systemic) of 131  92 seconds, during infusion (systemic) of 347  36 seconds, and from the
distal vasculature (limb) of 345  66 seconds. Distal limb bivalirudin levels were stable at 9755  3860 ng/mL during
clamp occlusion. Mean estimated blood loss was 332  191 mL with four patients (22%) requiring blood products. One
patient required revision of the proximal anastomosis during the initial hospitalization. At 30 days, all bypass operations
were patent with improvement of mean ankle-brachial index from 0.57 to 0.81. There were no deaths, myocardial
infarctions, or amputations in the 30-day postoperative period. Based on the Thrombolysis in Myocardial Infarction
classification for bleeding, one patient had major bleeding (>2 units of packed red blood cells), and three patients had
minor bleeding within the first 30 days.
Conclusions: Bivalirudin is a safe and effective anticoagulant for lower extremity bypass operations. Thrombosis beyond
the distal clamp was not seen. A comparative trial to standard anticoagulation is warranted. (J Vasc Surg 2010;52:
369-74.)The management of patients with peripheral arterial
disease (PAD) involves assessment and modification of the
risk factors affecting generalized atherosclerosis, often fol-
lowed by endovascular or surgical intervention to remedy
symptoms.1 For the vast majority of endovascular therapies
or open revascularization, unfractionated heparin is used
for anticoagulation during and sometimes after the proce-
dure. Although unfractionated heparin is commonly ad-
ministered during vascular procedures, there has been no
systematic study of the relationship between dose and
clinical outcome, vessel patency, or bleeding. Pharmaco-
logic limitations of unfractionated heparin are well de-
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doi:10.1016/j.jvs.2010.02.276scribed and include failure to inhibit thrombin bound to
fibrin,2 activation of platelets via the glycoprotein (GP)
IIb/IIIa receptor,3,4 nonspecific binding causing non-lin-
ear kinetics, unpredictable dose-response characteristics,5
and potential to cause clinically severe immune reactions via
the heparin-PF4 complex antigen (ie, heparin-induced
thrombocytopenia [HIT]).6 The presence of heparin-associated
antibodies has been documented in approximately 21% of
patients presenting with peripheral vascular disease.7 These
patients have a 2.6-fold increase in perioperative throm-
botic events. Clinically significant bleeding occurs in 4% to
14% of patients in most cases using heparin8 and is as high
as 35% in the presence of intravascular thrombolytics.9
Bivalirudin is a 20- amino acid polypeptide with a
molecular weight of 2180 daltons and is a direct thrombin
inhibitor (DTI). This agent directly and specifically inhibits
all known actions of thrombin. These include protease
actions such as conversion of fibrinogen to fibrin and direct
cellular signaling actions such as activation of platelets.
Engineered as an analogue of hirudin, bivalirudin binds to
thrombin by four glycine residues. Bivalirudin binds
thrombin with high affinity, but once bound, the active site
is cleaved off, allowing recovery of thrombin function.
Bivalirudin has a relatively short half-life (25 minutes)
and produces rapid, dose-dependent prolongation of the
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similarity to heparin and is not immunogenic given its small
size and secondary structure.10 In December 2000, the US
Food and Drug Administration approved bivalirudin under
the brand name of Angiomax (The Medicines Company,
Parsippany, NJ), as an anticoagulant in patients with unsta-
ble angina undergoing percutaneous coronary intervention
(PCI).
Bivalirudin has been used as a heparin alternative in
patients needing PCI and coronary artery bypass grafting
(CABG). Bivalirudin has been shown to be effective with
less bleeding complications. In contrast, bivalirudin may be
associated with thrombosis in settings of stagnant blood
flow since fresh bivalvirudin is needed to continue throm-
bin inhibition. Thus, there is a putative risk of “stasis
thrombosis” beyond the placement of a distal arterial clamp
where minimal new drug may circulate. This risk may be
increased in patients with peripheral arterial disease who
have minimal distal perfusion and need distal clamping for
surgical revascularization. The rationale for this pilot trial
was to evaluate the efficacy and safety of this agent in
patients undergoing lower extremity bypass. In addition,
sampling of blood beyond the distal clamp to allow under-
standing of bivalirudin pharmocokinetics was planned.
METHODS
Trial design. This study was designed as a phase IIIB,
prospective, single-arm, open-label trial of bivalirudin in-
jection in patients undergoing lower extremity bypass sur-
gery. The trial was conducted in compliance with applicable
US and International regulations (eg, US Code of Federal
Regulations and the Declaration of Helsinki) and Good
Clinical Practices (GCP). The use of bivalirudin in this trial
was under the auspices of a US Food and Drug Adminis-
tration (FDA) Investigational New Drug (IND) held by
The Medicines Company. The Medicines Company funded
this trial, and provided input into the protocol develop-
ment, but had no role in analysis or interpretation of the
data nor in the formulation of this publication. This project
was approved by the Cleveland Clinic Foundation’s Insti-
tutional Review Board, and subjects gave informed consent
prior to enrollment. The primary objectives of this study
were to evaluate the clinical efficacy and safety of bivalirudin
as an anticoagulant during lower extremity revasculariza-
tion by assessing:
● Death (all cause);
● Bleeding;
● Amputation;
● Urgent revascularization;
● Bivalirudin pharmacokinetics in areas of potential stasis
distal to vascular occlusion.
Patient selection. Between 2006 and 2007, 123 pa-
tients undergoing lower extremity bypass were screened,
yielding 18 out of a planned 20 patients meeting criteria for
enrollment. All patients had severe symptomatic athero-
sclerotic disease (disabling claudication, seven; rest pain,seven; ulceration, four) requiring lower extremity bypass.
Inclusion criteria were:
1. Patients at least 18 years of age;
2. Be a suitable candidate for lower extremity revascular-
ization;
3. Be able to provide signed informed consent before
initiation of any study-related procedures.
The exclusion criteria included:
1. Reoperative procedures;
2. Patients with recent hemorrhagic stroke;
3. Radiation injury in the region of proposed incision(s);
4. Patients who have received thrombolytic (urokinase,
tissue plasminogen activator [tPA], etc.) therapy within
the last 48 hours;
5. Bleeding diathesis or history of intracerebral mass,
aneurysm, arteriovenous malformation, or gastrointes-
tinal or genitourinary bleeding within the last 2 weeks;
6. Thrombocytopenia (platelet count 100,000 cells/
mm3) at baseline;
7. Ongoing treatment with warfarin. Patients previously
treated with warfarin were included if warfarin therapy
could be safely discontinued and baseline International
Normalized Ratio (INR) was 1.5 or prothrombin
time (PT) was 15 seconds in the absence of heparin
therapy;
8. Patients who received low-molecular-weight heparin
(LMWH)within 8 hours of study drug administration;
9. Patients who received heparin within 6 hours of study
drug administration;
10. Use of abciximab in the last 24 hours or use of eptifi-
batide or tirofiban within the last 12 hours;
11. Allergy to bivalirudin or any hirudin-derived drugs;
12. Contraindications to angiography;
13. Pregnancy;
14. Renal impairment: serum creatinine4.0 mg/dL OR
estimated creatinine clearance of 30 mL/min;
15. Patients enrolled in another investigational drug or
device study within the past 30 days;
16. Resistance to aspirin or clopidogrel;
17. Patients who required any concomitant coronary in-
tervention (eg, PCI, CABG).
Thirty-five patients met the inclusion/exclusion crite-
ria; 18 patients consented. The most common reasons for
exclusion included redo operation (55%), renal impairment
(17%), other medication issues (7%), and thrombocytope-
nia (2%).
Surgical procedures. Standard operative manage-
ment for lower extremity bypass was used. Bivalirudin was
used as the sole anticoagulant, and no heparin or other
anticoagulation was used, including dilute heparin flush
solutions. The sequence of events is outlined in the Fig.
Bivalirudin bolus (0.75 mg/kg intravenously [IV]) was
administered 5 minutes prior to vascular clamping, and an
infusion was started (1.75 mg/kg/h IV) and was contin-
ued until unclamping. During construction of the distal
anatomosis, sampling of the distal arterial blood was per-
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occluding the distal artery over the cannula with an elastic
loop. This allowed arterial samples of the distal (“stag-
nant”) blood. The samples were sent for bivalirudin levels
and ACT. If the ACT measured from the distal circulation
fell below 200 seconds at any time point during the
procedure, the protocol allowed the operator to bolus with
additional bivalirudin at a dose of 0.075 mg/kg, directly
into the distal vasculature. The postprocedure regimen
mandated that all patients continued aspirin postopera-
tively. In cases of poor lower extremity outflow, continued
postoperative antithrombotic therapy with bivalirudin
could be used at 0.25 mg/kg/h for up to 4 hours at the
discretion of the treating physician.
Data analyses. All patient data were collected and
stored in a Health Insurance Portability and Accountability
Act (HIPAA) compliant Oracle database. Periprocedure
data, associated morbidity, and mortality within 30 days of
the procedure were determined. Patient variables were
expressed as proportions for dichotomous variables and
mean  standard deviation for continuous variables. Pa-
tient data were standardized and analyzed.
Hemorrhage was assessed during hospitalization.
Hemorrhage was classified as major or minor according to
Thrombolysis in Myocardial Infarction (TIMI) criteria.11
Major hemorrhage was defined as:
Fig. Sequence of surgical and postprocedure events.● Intracranial hemorrhage, or● A fall in hemoglobin (Hgb) 5 g/dL (or 15% of
hematocrit).
Further criteria for major hemorrhage included in this
protocol were:
● Large operative hematoma requiring reoperation or
extended observation in the hospital, or
● Retroperitoneal hemorrhage, or
● Blood loss in patients of 2 units of whole blood or
packed red blood cells
Minor hemorrhage was defined as any overt bleeding
event that did not meet the criteria for a major hemorrhage
including:
● Gross hematuria or hematemesis, or
● A fall in Hgb between 3-5 g/dL (or 10% of hemato-
crit) with no bleeding site identified despite an effort to
find one.
Further criteria for minor hemorrhage included in this
protocol were:
● Small operative hematoma not requiring reoperation
or extended observation in the hospital.
RESULTS
Patients (n 18) with significant atherosclerotic occlu-
sive disease underwent lower extremity bypass with biva-
lirudin as the sole anticoagulant. These patients (mean age,
67 years) had the characteristic risk factors for atheroscle-
rosis: hypertension (67%), hyperlipidemia (61%), smoking
history (78%, current smokers 43%), and diabetes (50%).
The mean preoperative ankle-brachial index (ABI) was
0.57, with mostly femoral/popliteal occlusive disease.
These patients underwent femoral-popliteal (n  14) or
femoral-tibial (n  4) bypass using saphenous vein prefer-
entially (83%).
A weight-based dosing of bivalirudin was used in this
study with 0.75 mg/kg IV bolus immediately preceding
vascular clamp occlusion, followed by 1.75 mg/kg/h IV
infusion for the duration of surgery. The total bivalirudin
infusion time was 95  26 minutes (mean  standard
deviation). If, during the procedure, the ACT measure-
ment from the distal limb was 200 seconds, the protocol
allowed a bolus through the distal occlusive catheter, with
an additional 0.075 mg/kg IV. This was done in one
patient. Also, per protocol, an additional 0.25 mg/kg/h
infusion could be continued following the procedure for up
to 4 hours, at the discretion of the treating physician. This
was performed in 50% of cases (9/18), analogous to a
postoperative low-dose heparin infusion. Total bivalirudin
dosage administration was 337  105 mg (Table I).
Reliable anticoagulation was achieved with weight-
based dosing of bivalirudin. ACT values at baseline were
132  22 seconds (mean  standard deviation), obtained
via radial arterial sampling (systemic). Fiveminutes after the
bivalirudin bolus, ACT values were 349  37 seconds
(systemic). ACT values remained extremely stable with
weight-based dosing (Table II). Arterial samples from the
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nula directed to the distal artery during the distal anasto-
mosis. Samples were obtained every 5 to 10minutes during
the construction of the anastomosis with mostly 2 to 3
samples drawn. Average distal bivalirudin levels were 9755
3860 ng/mL during clamp occlusion. These levels re-
mained stable during the clamp period. At the beginning of
the distal anastomosis, ACT levels averaged 345  53
seconds (limb). Just prior to completion of the distal anas-
tomosis, ACT levels were 345  78 seconds (limb). The
mean operative time was 261 minutes, with a distal clamp
time of 33 minutes. At the end of the procedure, ACT
levels were returning to baseline but were still elevated at
273  58 seconds (systemic), despite complete operative
hemostasis.Mean estimated blood loss was 332 191mLwith
four patients (22%) requiring blood products.
At 30 days, all bypass operations were patent with
improvement of mean ABI from 0.57 to 0.81. There were
no deaths, myocardial infarctions, or amputations in the
30-day postoperative period. One patient required revision
of the proximal anastomosis during the initial hospitaliza-
tion after postoperative surveillance duplex identified ele-
vated velocities. Based on the TIMI classification for bleed-
ing, one patient had major bleeding (2 units of packed
red blood cells; Table III). This patient had a prolonged
tibial bypass operation (5 hours, 22 minutes) because of a
technical problem with the distal anastomosis, which re-
quired revision. Estimated blood loss was 800 mL, neces-
sitating intraoperative transfusion. No further bleeding/
transfusion was required in this patient. Three additional
patients had minor bleeding within the first 30 days.
DISCUSSION
The theoretical benefits of bivalvirudin for anticoagu-
lation include consistent thrombin inhibition and rapid
metabolism. A distinct pharmacological advantage is that
bivalirudin inhibits both fluid phase and fibrin-bound
thrombin with similar potency.12 Furthermore, heparins
cause platelet aggregation through binding and upregulation
of the platelet GPIIb/IIIa receptor. On the other hand,
bivalirudin inhibits platelet aggregation by blocking throm-
bin signaling to the protease-activated receptor (PAR) fam-
ily, which is themost potent switch for platelet activation.13
The effects on thrombin by bivalirudin are reversible.
Thrombin recognizes the drug as a substrate and cleaves
one active moiety, resulting in reduced affinity and dis-
placement of the remaining portion of the molecule by
Table I. Intraoperative anticoagulation parameters
(n  18)
Assay
Total bivalirudin
dosage 337  105 mg
Bivalirudin levels Infusion initiation 8710  1613 ng/mL
Infusion end 10570  5702 ng/mL
Continuous values represented as mean  SD.fibrinogen or other thrombin substrates. Thus, bivalirudinhas a predictable dose response. The plasma half-life of
bivalirudin is approximately 25 minutes in patients with
normal renal function. This allows anticoagulation only
during vascular clamping, decreased hemostasis times, and
avoidance of protamine administration. Lastly, there are no
known allergic reactions or risk of heparin-induced throm-
bocytopenia with bivalirudin.
Studies performed in the coronary bed provided rationale
for the current study. In patients with unstable angina under-
going PCI, bivalirudin significantly reduced the incidence of
ischemic and bleeding complications compared with hepa-
rin.14 In the Randomized Evaluation in PCI Linking Angio-
max to Reduced Clinical Events (REPLACE-2) trial, the
incidence of bleeding complications was significantly lower in
the bivalirudin group among patients undergoing PCI.15 The
frequency of the combined endpoints of death, myocardial
infarction, or urgent revascularization was similar with biva-
lirudin, and the provisional use of glycoprotein IIb/IIIa in-
hibitors (GPI) compared with the use of heparin plus GPI.
The short duration of action also translated into the practical
advantages of earlier sheath removal and hospital discharge.15
Long-term data from the REPLACE-2 trial showed overall
mortality at 1 year to be numerically lower in patients treated
with bivalirudin than in patients treated with heparin and to
represent a 24% reduction in the risk of death (1.89%vs 2.46%;
hazard ratio, 0.78; 95% confidence interval, 0.55-1.11; P 
.16).16
Bivalirudin has now been studied as an anticoagulant in
several series of patients undergoing percutaneous periph-
eral intervention as well. In the Angiomax Peripheral Pro-
cedure Registry of Vascular Events (APPROVE) study,
Allie et al evaluated bivalirudin in 505 patients undergoing
peripheral intervention using the same dose of 0.75 mg/kg
bolus followed by a 1.75 mg/kg/h infusion.17 Ischemic
events were low at 1.4%. Bleeding was also low with a TIMI
major hemorrhage rate of 0.4%. The authors concluded
that bivalirudin was associated with consistent anticoagula-
tion and safe in peripheral interventions.
Recently, bivalirudin has been studied in the context of
open cardiovascular surgery. Specifically patients with se-
vere coronary artery disease that required coronary artery
bypass have been randomized to bivalirudin vs standard
anticoagulation. The Evolution-Off study was a random-
ized, multicenter trial comparing heparin with protamine
reversal with bivalirudin in patients undergoing off-pump
coronary artery bypass.18 One hundred one patients were
given bivalirudin, and 56 patients received heparin with
protamine reversal. The mean age, demographics, and co-
morbidities were similar in both groups. Composite end-
points at discharge and at 12 weeks were similar in both
groups. Strokes (n 3) only occurred in patients receiving
heparin. Bleeding complications and the need for transfu-
sion were similar for both groups. Early reoperation for
bleeding was similar: bivalirudin group, 7.9% vs heparin
group, 5.4%. Published in the same year, the Evolution-
On study randomized patients undergoing CABG with
cardiopulmonary bypass to either heparin with protamine
reversal or bivalirudin.19 One hundred one patients were
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Adequate anticoagulation was achieved in all patients. Sim-
ilar to the Evolution-Off study, blood loss, transfusion
need, and duration of surgery were similar between the two
arms. Of note, the dose used in the bivalirudin group was
higher than the one described in this study with a 1 mg/kg
bolus and a 2.5 mg/kg/hour infusion. The pump tubing
was primed with bivalirudin prior to commencement of
cardiopulmonary bypass. A perioperative myocardial infarc-
tion occurred in 6.1% of patients receiving bivalirudin,
while 11.5% in the heparin group had a perioperative
myocardial infarction. Of note, there was a concern of
depletion of bivalirudin levels in areas of stasis or areas
isolated from the circuit, given the constant metabolism of
this drug. Avenues to prevent stasis and reduce stasis within
the venous reservoir were employed. These data from pro-
spective randomized trials indicate that the anticoagulation
with bivalirudin is predictable and consistent.
One of the theoretical concerns in using bivalirudin in
vascular surgery of the lower extremities is the possibility of
thrombosis distal to the distal occlusive clamp, occlusive
loop, or tourniquet. Because of the short half-life of biva-
lirudin, and the fact that it is cleaved by thrombin, it is
anticipated that circulating levels may decline if the drug is
not replenished by direct or collateral circulation. The rate
of decline of bivalirudin is not known because there are
multiple factors influencing its pharmacokinetics, including
the initial amount of drug, availability of new drug, and the
relative amount of circulating thrombin. Other modulators
of coagulation may have some effect as well. Patients with
severe peripheral vascular disease often have well-developed
collateral circulation. It is believed that this collateral circu-
lation, as well as diligent back-bleeding of the surgically-
occluded arteries may replenish circulating drug concentra-
Table II. Activated clotting time values (n  18)
Time Baseline 5 minutes after bolus Distal
Location Systemic Systemic
ACT value (seconds) 132 349
Minimum 93 288
Maximum 180 403
Standard deviation 22 37
ACT, Activated clotting time.
Table III. Primary endpoints
In hospital 30-day Comments
Death (all cause) 0 0
Myocardial infarction 0 0
Major hemorrhagea 1 2u PRBC
Minor hemorrhagea 3
Patency of bypass 100% 100%
Limb salvage 100% 100%
PBRC, Packed red blood cells.
aTIMI (Thrombolysis in Myocardial Infarction) criteria.tions to the arterially-occluded limb. Patients without pre-existing collaterals (ie, trauma patients, embolic lesions)
were not included in this trial and will require further study.
This may allowmodulating the dose of bivalirudin based on
preoperative variables.
Our results highlight the following. Based on the find-
ings of this pilot study, the concern over distal thrombosis
in the setting of stagnant blood with distal clampingmay be
unfounded. In lower extremity arteries, bivalirudin seemed
to provide anticoagulation for longer times than expected,
by in vitro testing using the bolus dose of 0.75 mg/kg and
continuous infusion of 1.75 mg/kg/hr. The salient clinical
observation is that the drug can be turned off 5 minutes
prior to completion of distal anastomosis, with the expec-
tation that anticoagulation will terminate 20 to 25 minutes
later. This may limit the amount of time waiting for hemo-
stasis prior to closing all wounds. We observed that there
was minimal bleeding from raw surfaces. We had no clinical
episodes of significant bleeding in the operating room with
predictable anticoagulation during these cases. Our clinical
observations were mirrored by the serum bioassays. Biva-
lirudin levels and ACTs stayed stable through the infusions
without extreme variation. This small pilot trial indicates
that bivalirudin is safe and effective for lower extremity
bypass. Given the small group of selected patients, further
larger trials are needed to confirm our findings. Studies
involving heterogeneous groups will allow generalizability
for patients with PAD. A comparative trial of bivalirudin to
standard anticoagulation with heparin is warranted.
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